Concerns on US FDA’s biosimilar guidance

There have been mixed reviews on the recent publishing of three final guidance’s by the US FDA. Some reviewer’s support the release of these documents, while others fear the documents led to the risk of “taking a copycat product.”

Two main groups that are concerned about these drafts are Patients for Biology Safety & Access (PBSA) and the Immune Deficiency Foundation (IDF). They believe that the guidance’s need to strengthen safety issues with biosimilar products and not focus on ‘diminishing transparency’. These two groups have sent a letter to the commissioner of FDA responding to the release of the guidance. To read quotes from the letter and learn more about the apprehensions for the guidance’s click here.

Obstacles Facing Biosimilars

Still in its infancy in the U.S., the industry faces some growing pains.

Life Science Accelerated

Pearl Pathways is a comprehensive life science product development services company. Every day we strive to provide our customers top quality service, unyielding ethics, and efficient services through our team of experts. Pearl Pathways supports biopharmaceutical, medical device, and diagnostic companies as well as life science service providers with clinical, regulatory, and quality compliance needs. Our full-service central IRB supports all aspects of human research.